Pheochromocytoma primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Biochemical screening for family members of MEN2 patients is mandatory.Genetic testing should be performed in first-degree relatives of a patient with proven germline ''RET'' mutation. | Biochemical screening for family members of [[MEN2]] patients is mandatory.Genetic testing should be performed in first-degree relatives of a patient with proven germline ''[[RET proto-oncogene|RET]]'' mutation. | ||
==Primary Prevention== | ==Primary Prevention== | ||
* According to the Endocrine Society, screening for '''''familial pheochromocytoma''''' is associated with many syndromes. [[Multiple endocrine neoplasia type 2|Multiple endocrine neoplasia]]<nowiki/>s (MEN2) is one of them. Biochemical screening for family members of MEN2 patients is mandatory. | * According to the Endocrine Society, screening for '''''[[familial pheochromocytoma]]''''' is associated with many syndromes. [[Multiple endocrine neoplasia type 2|Multiple endocrine neoplasia]]<nowiki/>s (MEN2) is one of them. Biochemical screening for family members of MEN2 patients is mandatory. | ||
* Biochemical screening for pheochromocytoma in pediatric patients with [[Von Hippel-Lindau tumor suppressor|VHL]] starting at 5 years of age with lifelong biochemical surveillance every year and the use of anatomic imaging when [[norepinephrine]] levels are elevated more than two times upper normal limits.<ref name="pmid26451910">{{cite journal| author=Aufforth RD, Ramakant P, Sadowski SM, Mehta A, Trebska-McGowan K, Nilubol N et al.| title=Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome. | journal=J Clin Endocrinol Metab | year= 2015 | volume= 100 | issue= 12 | pages= 4498-504 | pmid=26451910 | doi=10.1210/jc.2015-3045 | pmc=4667160 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26451910 }}</ref> | * Biochemical screening for pheochromocytoma in pediatric patients with [[Von Hippel-Lindau tumor suppressor|VHL]] starting at 5 years of age with lifelong biochemical surveillance every year and the use of anatomic imaging when [[norepinephrine]] levels are elevated more than two times upper normal limits.<ref name="pmid26451910">{{cite journal| author=Aufforth RD, Ramakant P, Sadowski SM, Mehta A, Trebska-McGowan K, Nilubol N et al.| title=Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome. | journal=J Clin Endocrinol Metab | year= 2015 | volume= 100 | issue= 12 | pages= 4498-504 | pmid=26451910 | doi=10.1210/jc.2015-3045 | pmc=4667160 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26451910 }}</ref> | ||
* Plasma fractionated metanephrines as the best test in this case. Normal values are enough to stop any further tests but if elevated results, 24-hour urinary fractionated | * Plasma fractionated metanephrines as the best test in this case. Normal values are enough to stop any further tests but if elevated results, 24-hour urinary [[Metanephrine|fractionated metanephrine]]<nowiki/>s should be done. | ||
=== '''Genetic testing''' should be performed in:<ref name="pmid24893135">{{cite journal| author=Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH et al.| title=Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. | journal=J Clin Endocrinol Metab | year= 2014 | volume= 99 | issue= 6 | pages= 1915-42 | pmid=24893135 | doi=10.1210/jc.2014-1498 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24893135 }}</ref> === | === '''Genetic testing''' should be performed in:<ref name="pmid24893135">{{cite journal| author=Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH et al.| title=Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. | journal=J Clin Endocrinol Metab | year= 2014 | volume= 99 | issue= 6 | pages= 1915-42 | pmid=24893135 | doi=10.1210/jc.2014-1498 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24893135 }}</ref> === | ||
* First-degree relatives of a patient with proven germline ''RET'' mutation | * First-degree relatives of a patient with proven germline ''[[RET proto-oncogene|RET]]'' mutation | ||
* Parents whose young children have MEN type2 | * Parents whose young children have [[Multiple endocrine neoplasia type 2|MEN type2]] | ||
* Patients with cutaneous lichen amyloidosis | * Patients with cutaneous lichen amyloidosis | ||
* Families whose infants or young children have Hirschsprung disease | * Families whose infants or young children have [[Hirschsprung disease]] | ||
* For high-risk children, screening for pheochromocytoma should begin by age 11 years and begin screening by age 16 years for moderate risk patients. Patients should be screened yearly by measuring plasma fractionated metanephrines. If positive, adrenal imaging (CT) or (MRI) should be performed. | * For high-risk children, screening for pheochromocytoma should begin by age 11 years and begin screening by age 16 years for moderate risk patients. Patients should be screened yearly by measuring [[Metanephrines|plasma fractionated metanephrines]]. If positive, adrenal imaging (CT) or (MRI) should be performed. | ||
* Patients with known ''RET'' mutations perform a prophylactic thyroidectomy. Children with the highest risk mutation should have thyroidectomy within the first years of life. Children with moderate risk mutations at age five years. | * Patients with known ''RET'' mutations perform a prophylactic [[thyroidectomy]]. Children with the highest risk mutation should have thyroidectomy within the first years of life. Children with moderate risk mutations at age five years. | ||
== References == | == References == |
Revision as of 14:09, 31 July 2017
Pheochromocytoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Pheochromocytoma primary prevention On the Web |
American Roentgen Ray Society Images of Pheochromocytoma primary prevention |
Risk calculators and risk factors for Pheochromocytoma primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Overview
Biochemical screening for family members of MEN2 patients is mandatory.Genetic testing should be performed in first-degree relatives of a patient with proven germline RET mutation.
Primary Prevention
- According to the Endocrine Society, screening for familial pheochromocytoma is associated with many syndromes. Multiple endocrine neoplasias (MEN2) is one of them. Biochemical screening for family members of MEN2 patients is mandatory.
- Biochemical screening for pheochromocytoma in pediatric patients with VHL starting at 5 years of age with lifelong biochemical surveillance every year and the use of anatomic imaging when norepinephrine levels are elevated more than two times upper normal limits.[1]
- Plasma fractionated metanephrines as the best test in this case. Normal values are enough to stop any further tests but if elevated results, 24-hour urinary fractionated metanephrines should be done.
Genetic testing should be performed in:[2]
- First-degree relatives of a patient with proven germline RET mutation
- Parents whose young children have MEN type2
- Patients with cutaneous lichen amyloidosis
- Families whose infants or young children have Hirschsprung disease
- For high-risk children, screening for pheochromocytoma should begin by age 11 years and begin screening by age 16 years for moderate risk patients. Patients should be screened yearly by measuring plasma fractionated metanephrines. If positive, adrenal imaging (CT) or (MRI) should be performed.
- Patients with known RET mutations perform a prophylactic thyroidectomy. Children with the highest risk mutation should have thyroidectomy within the first years of life. Children with moderate risk mutations at age five years.
References
- ↑ Aufforth RD, Ramakant P, Sadowski SM, Mehta A, Trebska-McGowan K, Nilubol N; et al. (2015). "Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome". J Clin Endocrinol Metab. 100 (12): 4498–504. doi:10.1210/jc.2015-3045. PMC 4667160. PMID 26451910.
- ↑ Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH; et al. (2014). "Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline". J Clin Endocrinol Metab. 99 (6): 1915–42. doi:10.1210/jc.2014-1498. PMID 24893135.